Pharmaceutical formulations and methods for treating metabolic disorders and liver diseases
By using compounds of general formula I structure and pharmaceutical carriers and diluents in pharmaceutical preparations, the problem of limited tolerance of GIP/GLP-1 dual receptor agonist at high doses is solved, and the fatty liver disease is achieved Effective treatment improves treatment compliance and effectiveness.
Patent Information
- Application Number
- CN202380028118.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-01-18
- Filing Date
- 2023-01-11
- Publication Date
- 2024-11-12
AI Technical Summary
The existing GIP/GLP-1 dual receptor agonists are limited to tolerance due to gastrointestinal adverse events at high doses, which affects the achievement of treatment compliance and effective doses, leading to the challenge of treating fatty liver disease.
A pharmaceutical preparation has been developed, comprising a compound having the structure of formula I or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier and diluent such as propylene glycol and pH buffering, for the prevention or treatment of fatty liver disease. , including non-alcoholic steatohepatitis and liver fibrosis.
By improving the tolerance and bioaccessibility of drugs, the effectiveness of the treatment of fatty liver disease is enhanced, the gastrointestinal side effects are reduced, and the patient compliance and effectiveness of treatment plans are improved.
Smart Images

Figure BDA0005045389990000021 
Figure BDA0005045389990000041 
Figure BDA0005045389990000051
